Peginterferon as Part of a Functional Cure Strategy for Hepatitis B: Is the Juice Worth the Squeeze?

Article Gastroenterology & Hepatology

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B

Norah S. Terrault et al.

Summary: This study aimed to assess whether combination strategies could enhance HBsAg loss in patients with chronic hepatitis B. The results showed that the combination treatment group had a HBsAg loss rate of 5.3% at week 240, while the monotherapy group had a rate of 4.1%. The use of a combination of tenofovir and peginterferon led to earlier HBsAg decline but did not increase the percentage of HBsAg clearance. In addition, HBeAg positivity and subgenotype A2 were strongly associated with HBsAg clearance.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Getting to HBV cure: The promising paths forward

Scott Fung et al.

Summary: Chronic HBV infection is a global health burden, and achieving a cure remains challenging due to the persistence of cccDNA, HBV-DNA integration, and impaired immune response. Current therapies include DAAs and immunomodulators, but there are still many obstacles to overcome for a complete cure of HBV.

HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT

Seng Gee Lim et al.

Summary: For patients with chronic hepatitis B (CHB), switching to or adding peginterferon to nucleoside analogues (NA) is more effective than continuing NA. Adding peginterferon has better safety and similar efficacy compared to switching.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology